North American Chapter of IFSO – Cardiovascular Risk Reduction from GLP-1 RA to MBS

Recorded Thursday, April 10, 2025

Recent breakthroughs highlighted the dramatic effect of GLP-1RAs and related pharmaceuticals in reversing the effects imposed by metabolic syndrome on cardiovascular health. These medications were shown to significantly ameliorate, if not markedly reverse, the lethal consequences of cardiovascular disease (MACE). While metabolic/bariatric surgeons had long recognized these beneficial attributes following metabolic/bariatric surgery, the discovery that these agents could result in similar health benefits was a revelation to many clinicians.

In this webinar, we reviewed the most current evidence of the beneficial effects of pharmacotherapy and surgery on metabolic syndrome, with a specific emphasis on cardiometabolic health. We were joined by a national authority on cardiovascular disease, Dr. Lydia Alexander, Past President of the Obesity Medicine Association, and Dr. Potluri, an Obesity Medicine specialist, to discuss how these advances shaped our current approach to patients with cardiometabolic disease and what the future might hold as progress continued in this exciting area of health care.

Obesity Medicine Perspective by Vani Potluri, MD
Focus: GLP-1 RAs, major adverse cardiovascular events (MACE), and obesity-related medical management (OMMs)

Surgical Perspective by Ali Aminian, MD, FACS
Focus: Major adverse cardiovascular events (MACE) and the role of metabolic and bariatric surgery

Panel Discussion
Exploring the national and global implications of GLP-1 RA and MBS interventions.

Moderators
Marina Kurian, MD, FACS, DABOM, DABS-FPMBS and Samer Mattar, MD